Target intelligence / Profile preview

T cell receptor alpha joining 11 (TRAJ11)

Target
TRAJ11
Molecular classification
Other (gene segment), Immunoglobulin superfamily as a part of TCR constructs
01

Overview

The T cell receptor alpha joining 11 (TRAJ11) is a genetic segment within the TCR alpha locus that encodes one of many possible joining regions for the variable part of the alpha chain of the T cell receptor. During T cell development in the thymus, TRAJ11 may be recombined with a variable (V) segment to help create the highly diverse antigen-binding site of the TCR. This process allows T cells to recognize millions of different peptide-MHC combinations. TRAJ11 itself does not code for a functional protein but contributes to the assembly and diversity of TCRs, which are critical for adaptive immunity. It is not a druggable target, nor does it have independent biological activity or role in diseases outside its contribution to TCR diversity. TRAJ11 is often confused as a protein, receptor, or drug target, but is actually a genetic segment integral to constructing the T cell receptor alpha chain via somatic recombination. T cell receptor as a whole is a receptor and therapeutic target, but individual joining segments are not. If you intended an actual protein or receptor, this entry is not appropriate.

Other names
TRAJ11
02

Mechanism of action

Not applicable

03

Biological functions

Diversification of T cell receptor alpha chain during lymphocyte developmentSupporting antigen recognition by contributing to the diversity of the TCR
04

Disease associations

None directly. TRAJ11 itself does not have recognized disease roles, but aberrant TCR recombination or repertoire may affect immune responses or predispose to autoimmune disease
05

Safety considerations

None specific; TRAJ11 does not itself present safety concerns
06

Biomarkers

TRAJ11 itself is not a direct biomarker, but usage or frequency of TRAJ segments in TCR repertoires may have diagnostic, prognostic, or research value in immune-related diseases

Beyond the preview

Go deeper on T cell receptor alpha joining 11 (TRAJ11).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor alpha joining 11 (TRAJ11).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call